Related Experiment Video
Updated: May 5, 2026
14:39
Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
Published on: November 4, 2010
34.4K
Propylthiouracil-induced bronchiolitis obliterans organizing pneumonia
Jaehee Lee1, Sun Ha Choi, Keum Ju Choi
1Department of Internal Medicine, Kyungpook National University, School of Medicine, South Korea.
Internal Medicine (Tokyo, Japan)
|December 3, 2013
Summary
Propylthiouracil (PTU) can cause rare but serious lung issues like bronchiolitis obliterans organizing pneumonia (BOOP). Early detection and stopping PTU treatment can resolve these pulmonary complications effectively.
Area of Science:
- Pulmonology
- Pharmacology
- Internal Medicine
Background:
- Propylthiouracil (PTU) is a common antithyroid medication for hyperthyroidism.
- Adverse events associated with PTU, though infrequent, can be severe, particularly pulmonary complications.
- Early identification of PTU-induced lung conditions is critical for patient outcomes.
Observation:
- A case study detailing bronchiolitis obliterans organizing pneumonia (BOOP) induced by Propylthiouracil (PTU).
- Pathological confirmation of PTU-induced BOOP was achieved through surgical lung biopsy.
- The patient presented with pulmonary opacity during PTU therapy.
Findings:
- Immediate withdrawal of PTU led to successful resolution of symptoms and radiographic abnormalities.
- Corticosteroid treatment was not required for recovery.
- This case highlights the potential for PTU to cause BOOP.
Implications:
- Propylthiouracil-induced BOOP should be considered in the differential diagnosis of pulmonary opacity in patients on PTU.
- Prompt diagnosis and PTU discontinuation are key to managing this rare adverse effect.
- This finding emphasizes the importance of vigilant monitoring for pulmonary complications in patients receiving PTU.
Related Concept Videos
01:24Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features
77
Chronic bronchitis is a key phenotype of chronic obstructive pulmonary disease (COPD), characterized by airway-centered inflammation and mucus overproduction. It develops from long-term exposure to harmful particles or gases, most commonly cigarette smoke, which triggers a persistent inflammatory response.Cellular and Structural ChangesInflammation initially affects the large bronchi and later the smaller airways, with infiltration by immune cells, including neutrophils, macrophages, and...
77
01:20Chronic Obstructive Pulmonary Disease-II: Pathophysiology
5.0K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
5.0K
01:28Asthma I: Introduction
311
Asthma is a chronic inflammatory disorder of the airways characterized by variable airflow obstruction and heightened bronchial responsiveness to a wide range of triggers. The underlying inflammation leads to airway swelling, mucus hypersecretion, and smooth muscle constriction, all of which narrow the airway lumen and impede airflow. Clinically, asthma presents with recurrent episodes of wheezing, shortness of breath, chest tightness, and coughing, symptoms that typically vary in intensity and...
311
01:23Chronic Obstructive Pulmonary Disease I: Introduction
71
Chronic obstructive pulmonary disease is a common, preventable, and treatable respiratory disorder characterized by persistent symptoms and progressive airflow limitation. This limitation results from a combination of small-airway disease (obstructive bronchiolitis) and parenchymal destruction (emphysema), both driven by chronic inflammation from exposure to harmful particles or gases.The disease includes two main pathological entities: emphysema, marked by destruction of alveolar walls and...
71
01:23Chronic Obstructive Pulmonary Disease II: Emphysema
155
Emphysema, a major phenotype of chronic obstructive pulmonary disease (COPD), is characterized by irreversible destruction of alveolar walls and permanent enlargement of distal airspaces. Unlike chronic bronchitis, which primarily affects the airways, emphysema predominantly involves the lung parenchyma, where structural damage leads to airflow limitation.PathophysiologyIt most commonly results from prolonged exposure to cigarette smoke and other toxic gases, particularly cigarette smoke.
155
01:19Antiasthma Drugs: Leukotriene Modifiers
2.2K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
2.2K